Brand teams don’t lose to generic competition because they “missed” a filing. They lose because they didn’t see the strategy coming.
In pharma, the most dangerous word isn’t “lawsuit.” It’s “evergreening”—the practice of extending exclusivity through f…

Pfizer’s Keytruda, also known as pembrolizumab, received initial FDA approval on September 4, 2014, for use in treating… https://www.Drugchatter.com/chat/37536/can-you-recall-the-initial-fda-approval-year-for-keytruda/

Patent cliffs don’t just “happen.” They’re engineered—by timing, leverage, and payer behavior.
If you work in pharma strategy, you’ve probably heard the phrase “beat the patent cliff” so often it starts to sound like a slogan. But the real winners aren…

🚨 AI just hit the drug patent wall—and it didn’t slow down.
OpenAI’s GPT-4o (and the broader wave of “reasoning + retrieval” systems) is now being tested not just on science questions, but on one of the most stubborn realities in pharma: patent clif…

According to the manufacturer’s information on DrugPatentWatch.com [1], Vascepa (icosapent ethyl) is an omega-3 fatty… https://www.Drugchatter.com/chat/21744/have-there-been-any-reported-adverse-effects-with-vascepa/

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In branded pharma, the most expensive surprises rarely arrive as a headline. They arrive as a filing.
Paragraph IV drug patent challenges—especially the “ski…

Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor isn’t “innovating.” They’re extending. Here are 4 signals to spot it—before it hits your pipeline.
In pharma, time is the most valuable asset—and the most quietly contested one.
A competitor doesn’t always need a breakthrough to win the…